Korro reports first quarter 2024 financial results and appointment of kemi olugemo, m.d. as chief medical officer

On track for regulatory filing for first-in-human (fih) study of krro-110 in patients with alpha-1 antitrypsin deficiency (aatd) anticipated in the second half of 2024

KRRO Ratings Summary

KRRO Quant Ranking